Cargando…

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

SIMPLE SUMMARY: The identification of activating mutations in specific genes in non-small cell lung cancer (NSCLC) has led to the development of targeted therapies, which are currently part of the algorithm for their management. The recommendations agree on first and second-line metastatic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Refeno, Valéry, Lamuraglia, Michele, Terrisse, Safae, Bonnet, Clément, Dumont, Clément, Doucet, Ludovic, Pouessel, Damien, Culine, Stephane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345514/ https://www.ncbi.nlm.nih.gov/pubmed/34359788 http://dx.doi.org/10.3390/cancers13153887

Ejemplares similares

Concomitant Bifocal Urothelial Carcinoma and Breast Tumor: Second Primary Cancer or Metastatic Spread to the Breast?
por: Dumont, Clément, et al.
Publicado: (2014)

Primary adenocarcinoma of the seminal vesicle
por: Terrisse, Safae, et al.
Publicado: (2017)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
por: Gauthier, Hélène, et al.
Publicado: (2012)

Very Fast Recovery of Acute Disseminated Intravascular Coagulation with Abiraterone Acetate in a Patient with Bone Metastases from Castrate-Resistant Prostate Cancer
por: Gauthier, Hélène, et al.
Publicado: (2014)

Disseminated Intravascular Coagulation with Enhanced Fibrinolysis Caused by Heart Metastasis of Bladder Urothelial Carcinoma
por: Helal, Clara, et al.
Publicado: (2022)

Impact of microbiota on breast cancer hormone therapy
por: Terrisse, Safae, et al.
Publicado: (2023)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
por: Terrisse, Safae, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
por: Puisset, Florent, et al.
Publicado: (2023)

Second Conference on Heavy Ion Collisions in the LHC era and beyond
por: Arleo, Francois, et al.
Publicado: (2015)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
por: Dumez, Herlinde, et al.
Publicado: (2009)

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
por: Chou, Wen-Ru, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Chai, Chee-Shee, et al.
Publicado: (2020)

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
por: Chiang, Anne C., et al.
Publicado: (2020)

3D-Printed Models for Surgical Planning in Complex Congenital Heart Diseases: A Systematic Review
por: Batteux, Clément, et al.
Publicado: (2019)

Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies
por: Lugand, Leonard, et al.
Publicado: (2022)

Being a Surgeon in the Pandemic Era
por: Chia, Clement LK.
Publicado: (2020)

Hierarchy: enhancing performances beyond limits
por: Sanchez, Clément
Publicado: (2020)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Electronics for LHC-era experiments and beyond
Publicado: (2008)

Particle Physics in the LHC Era and beyond
por: Altarelli, Guido
Publicado: (2010)

Looking beyond the post-genomic era
por: Falconer, Ester
Publicado: (2013)

Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization
por: Culine, Stéphane, et al.
Publicado: (2018)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Tyrosine phosphorylation of Grb14 by Tie2
por: Sturk, Celina, et al.
Publicado: (2010)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
por: Huang, Allen Chung-Cheng, et al.
Publicado: (2021)

The outside medical evacuation for cancer from Madagascar
por: Valéry, Refeno, et al.
Publicado: (2019)

Association of the tyrosine phosphorylated epidermal growth factor receptor with a 55-kD tyrosine phosphorylated protein at the cell surface and in endosomes
Publicado: (1992)

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2uf90d4h8209ntb0fi9vffu5o7